Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma

SIMPLE SUMMARY: Surrogate radiology-based endpoints such as progression-free survival (PFS) and objective response rate (ORR) are commonly used in oncology. However, their surrogacy with overall survival (OS) has not been evaluated in immunotherapy trials for hepatocellular carcinoma (HCC). We found...

Full description

Saved in:
Bibliographic Details
Published in:Cancers (Basel)
Main Authors: Cabibbo, Giuseppe, Celsa, Ciro, Enea, Marco, Battaglia, Salvatore, Rizzo, Giacomo Emanuele Maria, Busacca, Anita, Matranga, Domenica, Attanasio, Massimo, Reig, Maria, Craxì, Antonio, Cammà, Calogero
Format: Artigo
Language:Inglês
Published: MDPI 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7796103/
https://ncbi.nlm.nih.gov/pubmed/33396833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13010090
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items